🇺🇸 FDA
Patent

US 12281327

Lymphohematopoietic engineering using CAS9 base editors

granted A61KA61K40/11A61K40/31

Quick answer

US patent 12281327 (Lymphohematopoietic engineering using CAS9 base editors) held by Regents of the University of Minnesota expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Regents of the University of Minnesota
Grant date
Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K40/11, A61K40/31, A61K40/4211, A61P